AMY109 IV
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 23, 2020
Chugai announces 2020 1st quarter results
(Chugai Press Release)
- "Chugai started phase I study for STA551 for the treatment of solid tumors....A phase II study started in Japan for the oncolytic type 5 adenovirus OBP-301(telomelysin), an oncolytic virus therapy from Oncolys BioPharma Inc., in esophageal cancer. For the engineered antibody AMY109 from Chugai research, the Company started a phase I study in solid tumors."
Trial status • Esophageal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1